We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Novel Drug Protects Against Heart Attack and Stroke

By Biotechdaily staff writers
Posted on 06 Feb 2008
A trans-Atlantic partnership will work towards wrapping up the development of a drug designed to prevent cardiac ischemia and stroke by being both cardio-protective and neuro-protective.

Myocardial ischemia, which can be silent or symptomatic, is an intermediate condition in coronary artery disease during which the heart tissue is slowly or is suddenly starved of oxygen and other nutrients. More...
Eventually, the affected heart tissue will die. When blood flow is completely blocked to the heart, ischemia can lead to a heart attack. Ischemia can also occur in the arteries of the brain, where blockages can lead to a stroke. About 80-85% of all strokes are ischemic. Most blockages in the cerebral arteries are due to a blood clot, often in an artery narrowed by plaque.

The drug under investigation is QGC002, a novel recombinant protein that acts to protect against both myocardial ischemia and stroke. The drug was discovered by investigators at the French Institut National de la Santé et de la Recherche Médicale (INSERM), and their partner, Quantum Genomics Corp. (Jersey City, NJ, USA), will fund and conduct pre-clinical development and drug manufacturing. Investigators at Inserm will perform pharmacologic studies in relevant animal models of the targeted diseases.

"This partnership with Inserm provides QGC with a novel first-in-class drug that complements our pipeline,” said Mr. Lionel Ségard, CEO of Quantum Genomics. "It contributes further to enhance our ambition to provide innovative products to treat diseases with significant unmet medical needs.”

"This partnership with Quantum Genomics Corporation gives us a great opportunity to participate in the development of a novel biotherapy,” said Dr. Brigitte Onteniente, senior investigator at INSERM.


Related Links:
INSERM
Quantum Genomics Corporation

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.